Gastrointestinal Pharmacology

Correct Answer

B — Mesalamine

Rationale

Mesalamine (5-aminosalicylic acid) is classified as an aminosalicylate. Azathioprine is a thiopurine prodrug. Budesonide is a synthetic glucocorticoid. Methotrexate is a folate antagonist.

Correct Answer

D — Aminosalicylate prodrug in which 5-ASA is linked to a sulfapyridine carrier via an azo bond

Rationale

Sulfasalazine is classified as an aminosalicylate prodrug consisting of 5-aminosalicylic acid (mesalamine) linked to sulfapyridine via an azo bond. The remaining options describe azathioprine, budesonide, and methotrexate respectively.

Correct Answer

A — Thiopurine prodrug converted to 6-mercaptopurine, which generates active thioguanine nucleotides that terminate lymphocyte proliferation

Rationale

Azathioprine is a thiopurine prodrug that undergoes non-enzymatic conversion to 6-mercaptopurine. 6-mercaptopurine then enters three competing metabolic pathways, of which the anabolic pathway via hypoxanthine-guanine phosphoribosyltransferase is the therapeutically relevant one — generating 6-thioguanine nucleotides that are incorporated into lymphocyte DNA, causing chain termination and inducing apoptosis in activated lymphocytes. The accumulation of these metabolites takes 3 to 6 months, which is why azathioprine cannot be used for induction and requires corticosteroid or biologic bridge therapy while therapeutic levels build. Methotrexate is the folate antagonist (option B); budesonide is the glucocorticoid with high first-pass metabolism (option C).

Correct Answer

C — Budesonide

Rationale

Budesonide is classified as a synthetic glucocorticoid formulated for targeted ileal release. Mesalamine and sulfasalazine are aminosalicylates. Azathioprine is a thiopurine prodrug.

Correct Answer

B — Methotrexate

Rationale

Methotrexate is classified as a folate antagonist. Azathioprine is a thiopurine prodrug. Mesalamine is an aminosalicylate. Budesonide is a synthetic glucocorticoid.

Correct Answer

D — 6-mercaptopurine

Rationale

6-mercaptopurine is classified as a thiopurine whose metabolism is critically dependent on thiopurine methyltransferase (TPMT) activity. TPMT converts 6-mercaptopurine to an inactive methylated metabolite; patients with low TPMT activity accumulate active thioguanine nucleotides and are at risk for myelosuppression. Methotrexate is a folate antagonist. Mesalamine is an aminosalicylate. Budesonide is a synthetic glucocorticoid.

Correct Answer

A — G6PD activity — sulfapyridine can cause hemolytic anemia in deficient patients; and folate supplementation is started simultaneously because sulfapyridine inhibits intestinal folate absorption

Rationale

Sulfasalazine's adverse effects arise almost entirely from the sulfapyridine carrier, not from mesalamine. Two pre-treatment requirements are non-negotiable. First, screen for G6PD deficiency: sulfapyridine generates reactive oxidative metabolites that overwhelm the glutathione-dependent antioxidant system in G6PD-deficient red blood cells, causing hemolytic anemia. Second, start folic acid 1 mg daily simultaneously: sulfapyridine competitively inhibits intestinal folate transporters, impairing folate absorption and causing folate deficiency that can result in megaloblastic anemia and neural tube defects in pregnancy. Neither of these checks is required for sulfapyridine-free mesalamine formulations because the problematic carrier is absent. TPMT testing applies to thiopurines, not aminosalicylates.

Correct Answer

C — Combined oral plus rectal mesalamine, because topical rectal formulations add high local drug concentrations to the distal colon on top of systemic oral delivery

Rationale

For left-sided ulcerative colitis, combining oral and rectal mesalamine produces higher mucosal drug concentrations and better remission rates than either route alone. Oral formulations deliver mesalamine throughout the colon via luminal exposure during transit; rectal formulations (enemas, suppositories, foam) deliver high local concentrations topically to the distal colon and rectum with minimal systemic absorption. The two routes are complementary rather than redundant — oral delivery achieves proximal colonic exposure that topical formulations cannot reach, while rectal delivery achieves very high distal concentrations that oral dosing alone cannot match. This combination is first-line for mild to moderate active left-sided and extensive ulcerative colitis.

Correct Answer

D — Corticosteroids effectively suppress active inflammation but do not alter the natural history of IBD, do not prevent relapse, and cause significant cumulative systemic toxicity with chronic use

Rationale

The induction-only role of corticosteroids in IBD rests on two parallel realities: pharmacological and toxicological. Pharmacologically, corticosteroids suppress the acute inflammatory response effectively but do not modify the underlying immunopathological processes that drive chronic relapsing disease — patients who achieve steroid-induced remission relapse at the same rate as those who did not receive steroids. They do not prevent future flares and have no disease-modifying activity. Toxicologically, chronic corticosteroid use produces progressive HPA axis suppression, Cushingoid features, osteoporosis, hyperglycemia, hypertension, cataracts, and increased infection risk. The combination of no maintenance benefit with significant cumulative harm makes chronic corticosteroid use inappropriate in IBD, and steroid dependence — the inability to taper without relapse — is an explicit indication to escalate to immunomodulators or biologics.

Correct Answer

B — Allopurinol inhibits xanthine oxidase, blocking the catabolic conversion of 6-mercaptopurine to thiouric acid and causing massive thioguanine nucleotide accumulation that produces potentially fatal myelosuppression

Rationale

Xanthine oxidase normally catabolizes 6-mercaptopurine to inactive thiouric acid, providing one of three competing pathways that limit thioguanine nucleotide accumulation. Allopurinol is a potent xanthine oxidase inhibitor — this is its intended mechanism for reducing uric acid production in gout. When allopurinol is co-administered with azathioprine or 6-mercaptopurine at standard doses, the catabolic pathway is blocked, forcing all drug through the anabolic HGPRT pathway and generating extremely high thioguanine nucleotide concentrations. The result is severe, potentially fatal myelosuppression. If the combination is unavoidable, the azathioprine dose must be immediately reduced to 25 to 33 percent of the original dose with intensified blood count monitoring. Prescribing allopurinol without checking for thiopurine co-therapy is one of the most dangerous medication errors in gastroenterology.

Correct Answer

A — Therapeutic thioguanine nucleotide concentrations require 3 to 6 months to accumulate in lymphocytes; azathioprine is a maintenance agent and cannot provide rapid induction

Rationale

The slow onset of azathioprine is a fundamental pharmacokinetic limitation. 6-thioguanine nucleotides must accumulate to therapeutic concentrations within lymphocyte DNA over months of repeated dosing before clinically meaningful immunosuppression is achieved. This 3 to 6 month delay is not a failure of the drug — it is intrinsic to the mechanism, which depends on progressive DNA incorporation in dividing lymphocytes rather than immediate receptor occupancy. The clinical consequence is that azathioprine is always a maintenance agent requiring bridge therapy: corticosteroids or biologics provide rapid induction of remission while azathioprine levels build toward the maintenance threshold. Prematurely stopping the bridge therapy before thioguanine nucleotide levels are adequate leads predictably to relapse.

Correct Answer

D — Oral bioavailability is highly variable and decreases substantially at doses above 15 mg due to saturation of intestinal folate transporters, making systemic exposure unpredictable at IBD-relevant doses

Rationale

Methotrexate enters intestinal cells via the reduced folate carrier, a transporter with saturable kinetics. At low doses the carrier is not saturated and oral absorption is reasonably complete, but at the 15 to 25 mg weekly doses used in IBD, the transporter becomes saturated and absorption is both incomplete and highly variable — ranging from 25 to nearly 100 percent between patients and within the same patient on different occasions. This unpredictability makes oral dosing unsuitable when consistent systemic exposure is required for therapeutic efficacy. Intramuscular or subcutaneous injection bypasses this saturable intestinal transporter, providing reliable and reproducible systemic concentrations. Hepatotoxicity occurs with both routes and is related to cumulative dose, not route of administration.

Correct Answer

C — Methotrexate's adverse effects in rapidly dividing non-immune tissues arise from dihydrofolate reductase inhibition; folic acid reduces mucositis, nausea, and cytopenias without impairing the adenosine-mediated anti-inflammatory mechanism

Rationale

This question exploits the dual-mechanism feature of low-dose methotrexate. The anti-inflammatory effect at IBD doses operates through the adenosine pathway — independent of dihydrofolate reductase inhibition. The adverse effects (mucositis, nausea, alopecia, cytopenias) arise from DHFR inhibition in rapidly dividing non-immune tissues such as gastrointestinal mucosa and bone marrow. Folic acid supplementation replenishes the tetrahydrofolate pool in these rapidly dividing cells, reducing DHFR-inhibition-dependent toxicity without rescuing immune cells from the adenosine-mediated immunosuppression that is the therapeutic target. This mechanistic dissociation is why folic acid can reduce toxicity without reducing anti-inflammatory efficacy — they operate through different pathways.

Correct Answer

B — Clarithromycin inhibits CYP3A4, blocking budesonide first-pass metabolism and markedly increasing systemic budesonide exposure with attendant HPA axis suppression and Cushingoid risk

Rationale

Budesonide's favorable adverse effect profile depends entirely on its extensive first-pass CYP3A4 hepatic metabolism, which reduces systemic bioavailability to 10 to 15 percent. Clarithromycin is a potent CYP3A4 inhibitor. Co-administration blocks budesonide's first-pass extraction, causing systemic budesonide exposure to increase dramatically — potentially to levels comparable to equivalent doses of prednisone. The clinical consequence is loss of the adverse effect advantage that made budesonide the preferred agent in the first place: HPA axis suppression, Cushingoid features, and bone density loss all increase substantially. The same interaction applies to azole antifungals and HIV protease inhibitors. When a CYP3A4 inhibitor is required, reducing the budesonide dose or switching to an alternative steroid should be considered.

Correct Answer

D — Sulfapyridine generates oxidative metabolites that overwhelm the G6PD-deficient red cell's glutathione-dependent antioxidant system, causing oxidative hemolysis

Rationale

G6PD is the rate-limiting enzyme in the hexose monophosphate shunt, which generates NADPH required to maintain glutathione in its reduced (active) form. Reduced glutathione is the primary antioxidant defense against oxidative damage to hemoglobin and red cell membranes. Sulfapyridine generates reactive oxidative metabolites during its metabolism. In G6PD-sufficient patients, these are neutralized by glutathione. In G6PD-deficient patients, insufficient NADPH means glutathione cannot be regenerated, and oxidative damage to hemoglobin produces Heinz bodies that are removed as bite cells by splenic macrophages, causing acute intravascular and extravascular hemolytic anemia. The peripheral smear findings — bite cells and fragmented cells — are pathognomonic. This is exactly why G6PD screening is mandatory before sulfasalazine is started.

Correct Answer

A — Absent TPMT activity forces all 6-mercaptopurine through the HGPRT anabolic pathway, generating extremely high thioguanine nucleotide concentrations that cause severe myelosuppression

Rationale

In a TPMT poor metabolizer, the enzyme responsible for converting 6-mercaptopurine to inactive 6-methylmercaptopurine is absent. With the methyltransferase pathway eliminated, all 6-mercaptopurine that is not catabolized by xanthine oxidase is channeled exclusively through the HGPRT anabolic pathway, generating thioguanine nucleotide concentrations many times higher than those in normal metabolizers receiving the same dose. These supraphysiological thioguanine nucleotide levels cause profound, potentially fatal myelosuppression — pancytopenia with life-threatening neutropenia. The CPIC guidelines recommend either avoiding thiopurines entirely in poor metabolizers or using approximately 10 percent of the standard dose with intensified monitoring. TPMT testing before initiating azathioprine or 6-mercaptopurine is mandatory precisely to identify these patients.

Correct Answer

C — Allopurinol inhibits xanthine oxidase, eliminating a major catabolic route for 6-mercaptopurine and causing massive thioguanine nucleotide accumulation that produces severe myelosuppression

Rationale

This patient has allopurinol-thiopurine interaction-induced myelosuppression — one of the most dangerous drug interactions in gastroenterology. Allopurinol's mechanism as a uricosuric agent is inhibition of xanthine oxidase, the same enzyme that catabolizes 6-mercaptopurine to inactive thiouric acid. With xanthine oxidase blocked, 6-mercaptopurine is shunted entirely to the HGPRT anabolic pathway, generating thioguanine nucleotide concentrations that are four to five times higher than at baseline azathioprine dosing. The result is severe myelosuppression — leukopenia, neutropenia, oral ulcers, and infection risk — as demonstrated by this patient's WBC of 0.8. If allopurinol is required alongside a thiopurine, the azathioprine dose must be immediately reduced to 25 to 33 percent of the original before starting allopurinol. Checking the medication list for thiopurines before prescribing allopurinol is a patient safety imperative.

Correct Answer

B — Methotrexate is teratogenic and abortifacient — it inhibits trophoblast proliferation and fetal folate metabolism, causing spontaneous abortion and major congenital malformations; it must be discontinued at least 3 months before attempted conception

Rationale

Methotrexate carries an absolute contraindication in pregnancy. Its DHFR inhibition blocks folate metabolism in the rapidly dividing trophoblast cells of the early placenta, impairing implantation and causing spontaneous abortion. In fetuses that survive early exposure, folate-dependent neural tube closure and organogenesis are disrupted, producing the aminopterin-methotrexate syndrome — craniosynostosis, skeletal abnormalities, and central nervous system defects. This is intentional when methotrexate is used in combination with mifepristone for pregnancy termination; it is catastrophic in unintended pregnancy. The 3-month washout period allows clearance of methotrexate polyglutamates from tissues. Reliable contraception must be maintained throughout therapy and for at least 3 months after the last dose, and this must be documented at every prescription renewal.